hematologic disease
Conditions
Interventions
Group 1 vs Group 2:donor lymphocyte infusion combined with desetabine or azacytidine
Sponsors
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age: 14-70 years old (including 14, 70 years old), gender unlimited; 2. Myeloid tumor patients who have undergone allogeneic hematopoietic stem cell transplantation (allo HSCT), including but not limited to acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), etc; 3. Patients diagnosed as relapse of molecular biology after transplantation within 1 month should be reexamined within 2 weeks; 4. Patients who voluntarily participate in the trial and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with ECoG physical condition score >= 3; 2. Patients whose estimated survival time is less than 3 months; 3. Patients with hematological recurrence after transplantation; 4. Patients who are in the process of 3-4 degrees of severe GVHD without DLI; 5. Patients who are known to be allergic to azacytidine or dicithabine; 6. Patients who may not be able to complete the study due to other reasons or who are considered unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate to treatment;Treatment-emergent adverse events;median OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| quantification of immunoglobulin;lymphocyte subpopulations;whole transcriptomeanalysis of lymphocytes; | — |
Countries
China
Contacts
Public ContactYang Donglin
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Outcome results
None listed